Choi J, et al. - Researchers conducted a Korean nationwide population cohort study of 24,156 treatment-naive adult patients with chronic hepatitis B (CHB) infection to compare the risk of hepatocellular carcinoma (HCC) and death or liver transplant with entecavir vs tenofovir treatment in patients with CHB infection. Outcomes revealed a significantly lower risk of HCC and mortality in relation to tenofovir vs entecavir treatment. Data validation was done in a hospital cohort of 2,701 treatment-naive adult patients with CHB infection.